The growing prevalence of chronic disorders such as diabetes and obesity is driving the demand for peptide therapeutics such as insulin and GLP-1 receptor agonists. Furthermore, the growing aged population is adding to the disease burden.
Additionally, the new technological advancements in synthesis of peptides is bolstering the peptide API market. Peptide APIs (Active Pharmaceutical Ingredients) are biologically active compounds made of amino acids that are essential for many therapeutic uses, especially in the management of metabolic diseases.
GLP-1 agonists like liraglutide and semaglutide are examples of peptide APIs used to improve insulin secretion and control blood sugar levels. Furthermore, insulin is a well-known peptide API that is necessary for controlling diabetes by facilitating glucose uptake in cells.
Manufacturers are engaged in producing peptide APIs commercially. Peptide API manufacturers invest heavily in research and development activities to ensure high-quality, effective products while adhering to stringent regulatory standards. With the rising demand for peptide therapeutics, these companies are expanding their capabilities to meet the growing needs of the healthcare industry.
Peptides, which usually consist of less than 50 amino acids and are short chains of amino acids linked by peptide bonds, are vital to several biological processes. Peptide APIs are categorized into multiple types, such as hormones, enzymes, and signaling chemicals. Insulin and GLP-1 agonists are examples of hormonal peptides that control glucose homeostasis and metabolic processes.
Angiotensin-converting enzyme (ACE) inhibitors are an example of an enzymatic peptide that is engaged in biochemical reactions that influence blood pressure. Moreover, recombinant DNA technology or natural sources can be used to derive therapeutic peptides, enabling customized treatments in fields including immunology, endocrinology, and oncology.
Several companies across the globe are engaged in offering peptide APIs for development of several life-saving therapeutics. These therapeutics are essential for managing a variety of medical conditions. GLP-1 medications have been increasingly popular in recent years due to their ability to effectively manage type 2 diabetes and encourage weight loss.
Healthcare professionals are starting to prioritize these treatments owing to their dual advantages, as knowledge regarding connections between diabetes and obesity has surfaced. Their usage has been further bolstered by clinical research showing notable improvements in cardiovascular outcomes and glycemic management.
Patients now have an easier access to and convenience with these medications due to the development of novel formulations and delivery systems, such as once-weekly injections and oral alternatives. GLP-1 agonist prescriptions have significantly increased as a result of this increasing acceptance among physicians and patients, which has resulted in a significant shift in diabetes management strategies.
| Attribute | Detail |
|---|---|
| Peptide API Drivers |
|
Chronic diseases including diabetes, heart disease, stroke, and cancer have witnessed a tremendous rise over the years, and are the leading causes of morbidity and mortality worldwide. The global cost burden of chronic diseases is estimated to reach US$ 47 Tn by 2030
Since the early 1900s, an epidemiological transition has been taking place from infectious diseases to non-communicable diseases. The transition can be ascribed to improved nutrition, sanitation, and the other public health successes along with improved medical technology. Since 1950s, heart diseases have been the leading cause of mortality in the U.S.
In 2020, 523 million people were estimated to be suffering from some form of cardiovascular disorder, while nearly 18 million deaths were caused due to such disorders, which represents ~32% of all deaths, across the globe.
As per data from the American Community Survey, the American Hospital Association Survey, and the Centers for Disease Control and Prevention’s PLACES, 129 million individuals in the U.S. are anticipated to have at least one major chronic disorder.
Of these, 42% individuals have two or more chronic conditions, while 12% have five or more such conditions. About 90% of the annual healthcare expenditure (US$ 4.1 Tn) can be ascribed to management and treatment of chronic conditions.
The use of cutting-edge technologies in peptide synthesis has made it possible to produce cost-effective and efficient peptide APIs. The market for peptide APIs has expanded as a result of advancements in liquid-phase peptide synthesis (LPPS), solid-phase peptide synthesis (SPPS), and recombinant DNA technology.
The SPPS procedure has been simplified with the advent of automated synthesizers, enabling quick synthesis of many peptides at once. Up to 192 distinct sequences can be handled simultaneously by modern synthesizers, thereby cutting down on time of synthesis and increasing reproducibility.
Further, by employing microwave energy to increase reaction rates, microwave-assisted synthesis shortens downtime and may even increase yields. This process speeds up the synthesis of peptides.
Additionally, advances in liquid-phase synthesis techniques have made it possible to synthesize longer peptides that are difficult to create with SPPS alone. These techniques may be useful in some situations where the stability and solubility of the peptide are essential.
The peptide API market segmentation based on drug class includes GLP-1 receptor agonists, insulin, and other peptides. GLP-1 receptor agonists currently hold a significant market share in the overall peptide API market.
The GLP-1 receptor agonist segment accounts for highest growth rate in the peptide API owing to increasing adoption of such therapeutics. By controlling blood sugar levels, GLP-1 medications have shown to be quite successful in the management of type 2 diabetes. They are a desirable alternative for treating obesity because they have also shown to have a substantial impact on weight loss.
According to the peptide API industry report, based on route of administration, the market is classified into oral and parenteral. The parenteral segment dominates the market. The parenteral segment accounts for the largest revenue share as majority of the peptide therapeutics are administered via injections.
In the gastrointestinal tract, digestive enzymes have the ability to break down peptides. They have poor oral bioavailability since they cannot withstand the severe conditions of the stomach and intestines without special modifications. Because of this, the majority of peptide medications are designed for parenteral delivery, which completely avoids the digestive system and involves subcutaneous or intravenous injections.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest peptide API market analysis, North America held dominant share in 2023. Advancement of healthcare infrastructure, high investments in research, and augmented healthcare finances are driving market dynamics in the region.
Expansion of the peptide API Market in North America is primarily ascribed to the high incidence rate of chronic disorders and the high geriatric population in the region. Peptide therapies are developed and marketed with the backing of a strong healthcare system in North America, especially in the United States.
This comprises substantial manufacturing capabilities, a robust network of clinical trial centers, and a significant investment in biotechnology and pharmaceutical research. Several peptide API manufacturers are based in Europe where considerable growth in market share is anticipated during the forecast period.
Over the years, there has been a notable increase in the proportion of older adults in the Asia Pacific region, rising from 4% to 10% between 1970 and 2023, and projected to reach 19% by 2050. Expansion of the peptide API market in Asia Pacific at the highest CAGR is ascribed to the surge in demand for novel peptide therapeutics.
Furthermore, the peptide API industry value in the region is anticipated to rise due to increase in commercialization, rise in adoption of GLP-1 receptor agonist drugs, and entry of multinational firms within the marketplace.
As peptide API manufacturers are constantly innovating to improve product capabilities, innovative therapeutics are being introduced for better therapeutic efficiency.
Eli Lilly and Company, Sanofi, Novo Nordisk, AstraZeneca, GlaxoSmithKline, PegBio Co. Ltd., Amgen Inc., Pfizer Inc., Innovent Biologics, Sun Pharmaceuticals, Boehringer Ingelheim, Biocon, and Wockhardt Ltd. are the prominent peptide API market players.
Each of these players has been have been profiled in the peptide API market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2023 | US$ 9.2 Bn |
| Forecast Value in 2034 | More than US$ 94.2 Bn |
| CAGR | 22.4% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global peptide API market was valued at US$ 9.2 Bn in 2023
The global peptide API business is projected to reach more than US$ 94.2 Bn by the end of 2034
The CAGR is anticipated to be 22.4% from 2024 to 2034
Eli Lilly and Company, Sanofi, Novo Nordisk, AstraZeneca, GlaxoSmithKline, Pegbio Co. Ltd., Amgen Inc., Pfizer Inc., Innovent Biologics, Sun Pharmaceuticals, Boehringer Ingelheim, Biocon, and Wockhardt Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Peptide API Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Peptide API Market Analysis and Forecasts, 2020-2034
4.4.1. Market Value (US$ Bn) and Volume Projections (Kg)
5. Key Insights
5.1. Epidemiology of Diabetes and Obesity across Key Countries / Regions
5.2. Recent Technological Advancements in GLP-1 Receptor Agonist Therapeutics Industry
5.3. Recent Technological Advancements in Insulin Therapeutics Industry
5.4. GLP-1 Receptor Agonist Therapeutics Pricing Trends
5.5. Insulin Therapeutics Pricing Trends
5.6. Clinical Trials Analysis
6. Global Peptide API Market Analysis and Forecasts, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value, Volume and Patient Population Forecast By Drug Class, 2020-2034
6.3.1. GLP-1 Receptor Agonist
6.3.2. Insulin
6.3.3. Other Peptide Classes
6.4. Market Attractiveness By Drug Class
7. Global Peptide API Market Analysis and Forecasts, By Product Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value, Volume and Patient Population Forecast By Product Type, 2020-2034
7.3.1. GLP-1 Receptor Agonist Oral Formulations
7.3.2. GLP-1 Receptor Agonist Injectables
7.3.3. Insulin Injectables
7.3.4. Other Peptides
7.4. Market Attractiveness By Product Type
8. Global Peptide API Market Analysis and Forecasts, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value, Volume and Patient Population Forecast By Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness By Route of Administration
9. Global Peptide API Market Analysis and Forecasts, By Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value, Volume and Patient Population Forecast By Application, 2020-2034
9.3.1. Type 2 Diabetes Mellitus
9.3.2. Type 1 Diabetes
9.3.3. Obesity
9.3.4. Non-alcoholic Fatty Liver Disease
9.3.5. Others
9.4. Market Attractiveness By Application
10. Global Peptide API Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value, Volume and Patient Population Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Peptide API Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value, Volume and Patient Population Forecast By Drug Class, 2020-2034
11.2.1. GLP-1 Receptor Agonist
11.2.2. Insulin
11.2.3. Other Peptide Classes
11.3. Market Value, Volume and Patient Population Forecast By Product Type, 2020-2034
11.3.1. GLP-1 Receptor Agonist Oral Formulations
11.3.2. GLP-1 Receptor Agonist Injectables
11.3.3. Insulin Injectables
11.3.4. Other Peptides
11.4. Market Value, Volume and Patient Population Forecast By Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value, Volume and Patient Population Forecast By Application, 2020-2034
11.5.1. Type 2 Diabetes Mellitus
11.5.2. Type 1 Diabetes
11.5.3. Obesity
11.5.4. Non-alcoholic Fatty Liver Disease
11.5.5. Others
11.6. Market Value, Volume and Patient Population Forecast By Country, 2020-2034
11.6.1. U.S.
11.6.2. Canada
12. Competition Landscape
12.1. Market Player - Competition Matrix (By Tier and Size of companies)
12.2. Market Share Analysis By Company (2023)
12.3. Competitive Dashboard
12.3.1. By Region
12.3.2. By Drug Class
12.4. Competitive Snapshot
12.5. Company Profiles
12.5.1. Eli Lilly and Company
12.5.1.1. Company Overview
12.5.1.2. Financial Overview
12.5.1.3. Product Portfolio
12.5.1.4. Business Strategies
12.5.1.5. Recent Developments
12.5.2. Sanofi S.A.
12.5.2.1. Company Overview
12.5.2.2. Financial Overview
12.5.2.3. Product Portfolio
12.5.2.4. Business Strategies
12.5.2.5. Recent Developments
12.5.3. Novo Nordisk
12.5.3.1. Company Overview
12.5.3.2. Financial Overview
12.5.3.3. Product Portfolio
12.5.3.4. Business Strategies
12.5.3.5. Recent Developments
12.5.4. AstraZeneca
12.5.4.1. Company Overview
12.5.4.2. Financial Overview
12.5.4.3. Product Portfolio
12.5.4.4. Business Strategies
12.5.4.5. Recent Developments
12.5.5. GlaxoSmithKline
12.5.5.1. Company Overview
12.5.5.2. Financial Overview
12.5.5.3. Product Portfolio
12.5.5.4. Business Strategies
12.5.5.5. Recent Developments
12.5.6. PegBio Co. Ltd.
12.5.6.1. Company Overview
12.5.6.2. Financial Overview
12.5.6.3. Product Portfolio
12.5.6.4. Business Strategies
12.5.6.5. Recent Developments
12.5.7. Amgen Inc.
12.5.7.1. Company Overview
12.5.7.2. Financial Overview
12.5.7.3. Product Portfolio
12.5.7.4. Business Strategies
12.5.7.5. Recent Developments
12.5.8. Pfizer Inc.
12.5.8.1. Company Overview
12.5.8.2. Financial Overview
12.5.8.3. Product Portfolio
12.5.8.4. Business Strategies
12.5.8.5. Recent Developments
12.5.9. Innovent Biologics, Inc.
12.5.9.1. Company Overview
12.5.9.2. Financial Overview
12.5.9.3. Product Portfolio
12.5.9.4. Business Strategies
12.5.9.5. Recent Developments
12.5.10. Sun Pharmaceutical Industries Limited
12.5.10.1. Company Overview
12.5.10.2. Financial Overview
12.5.10.3. Product Portfolio
12.5.10.4. Business Strategies
12.5.10.5. Recent Developments
12.5.11. Boehringer Ingelheim
12.5.11.1. Company Overview
12.5.11.2. Financial Overview
12.5.11.3. Product Portfolio
12.5.11.4. Business Strategies
12.5.11.5. Recent Developments
12.5.12. Biocon Limited
12.5.12.1. Company Overview
12.5.12.2. Financial Overview
12.5.12.3. Product Portfolio
12.5.12.4. Business Strategies
12.5.12.5. Recent Developments
12.5.13. Wockhardt
12.5.13.1. Company Overview
12.5.13.2. Financial Overview
12.5.13.3. Product Portfolio
12.5.13.4. Business Strategies
12.5.13.5. Recent Developments
List of Tables
Table 01: Global Peptide API Market Value (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 02: Global Peptide API Market Volume (Kg) Forecast, by Drug Class, 2020-2034
Table 03: Global Peptide API Market, by Drug Class (Patient Population) (Bn), 2020-2034
Table 04: Global Peptide API Market Value (US$ Bn) Forecast, by Product Type, 2020-2034
Table 05: Global Peptide API Market Volume (Kg) Forecast, by Product Type, 2020-2034
Table 06: Global Peptide API Market, Product Type (Patient Population) (Bn), 2020-2034
Table 07: Global Peptide API Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 08: Global Peptide API Market Volume (Kg) Forecast, by Route of Administration, 2020-2034
Table 09: Global Peptide API Market, by Route of Administration (Patient Population) (Bn), 2020-2034
Table 10: Global Peptide API Market Value (US$ Bn) Forecast, by Application, 2020-2034
Table 11: Global Peptide API Market Volume (Kg) Forecast, by Application, 2020-2034
Table 12: Global Peptide API Market, by Application (Patient Population) (Bn), 2020-2034
Table 13: Global Peptide API Market Value (US$ Bn) Forecast, by Region, 2020-2034
Table 14: Global Peptide API Market Volume (Kg) Forecast, by Region, 2020-2034
Table 15: Global Peptide API Market, by Region (Patient Population) (Bn), 2020-2034
Table 16: North America Peptide API Market Value (US$ Bn) Forecast, by Country, 2020-2034
Table 17: North America Peptide API Market Volume (Kg) Forecast, by Country, 2020-2034
Table 18: North America Peptide API Market, (Patient Population) (Bn) 2020-2034
Table 19: North America Peptide API Market Value (US$ Bn) Forecast, by Drug Class, 2020-2034
Table 20: North America Peptide API Market Volume (Kg) Forecast, by Drug Class, 2020-2034
Table 21: North America Peptide API Market, by Drug Class (Patient Population) (Bn), 2020-2034
Table 22: North America Peptide API Market Value (US$ Bn) Forecast, by Product Type, 2020-2034
Table 23: North America Peptide API Market Volume (Kg) Forecast, by Product Type, 2020-2034
Table 24: North America Peptide API Market, Product Type (Patient Population) (Bn), 2020-2034
Table 25: North America Peptide API Market Value (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 26: North America Peptide API Market Volume (Kg) Forecast, by Route of Administration, 2020-2034
Table 27: North America Peptide API Market, by Route of Administration (Patient Population) (Bn), 2020-2034
Table 28: North America Peptide API Market Volume (Kg) Forecast, by Application, 2020-2034
Table 29: North America Peptide API Market Volume (Kg) Forecast, by Application, 2020-2034
Table 30: North America Peptide API Market, by Application (Patient Population) (Bn), 2020-2034
List of Figures
Figure 01: Global Peptide API Market Value (US$ Bn) Forecast, 2020-2034
Figure 02: Global Peptide API Market Value Share, by Drug Class, 2023
Figure 03: Global Peptide API Market Value Share, by Product Type, 2023
Figure 04: Global Peptide API Market Value Share, by Route of Administration, 2023
Figure 05: Global Peptide API Market Value Share, by Application, 2023
Figure 06: Global Peptide API Market Value Share, by Region, 2023
Figure 07: Global Peptide API Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
Figure 08: Global Peptide API Market Share Analysis, by Drug Class, 2023
Figure 09: Global Peptide API Market Share Analysis, by Drug Class, 2034
Figure 10: Global Peptide API Market Volume (Kg) Share Analysis, by Drug Class, 2023 and 2034
Figure 11: Global Peptide API Market Share Analysis, by Drug Class, 2023
Figure 12: Global Peptide API Market Share Analysis, by Drug Class, 2034
Figure 13: Global Peptide API Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 14: Global Peptide API Market Value (US$ Bn), by GLP-1 Receptor Agonist, 2020-2034
Figure 15: Global Peptide API Market Value Share Analysis, by GLP-1 Receptor Agonist, 2023 and 2034
Figure 16: Global Peptide API Market Value (US$ Bn), by Insulin, 2020-2034
Figure 17: Global Peptide API Market Value Share Analysis, by Insulin, 2023 and 2034
Figure 18: Global Peptide API Market Value (US$ Bn), by Other Peptide Classes, 2020-2034
Figure 19: Global Peptide API Market Value Share Analysis, by Other Peptide Classes, 2023 and 2034
Figure 20: Global Peptide API Market Volume (Kg), by GLP-1 Receptor Agonist, 2020-2034
Figure 21: Global Peptide API Market Volume Share Analysis, by GLP-1 Receptor Agonist, 2023 and 2034
Figure 22: Global Peptide API Market Volume (Kg), by Insulin, 2020-2034
Figure 23: Global Peptide API Market Volume Share Analysis, by Insulin, 2023 and 2034
Figure 24: Global Peptide API Market Volume (Kg), by Other Peptide Classes, 2020-2034
Figure 25: Global Peptide API Market Volume Share Analysis, by Other Peptide Classes, 2023 and 2034
Figure 26: Global Peptide API Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
Figure 27: Global Peptide API Market Share Analysis, by Product Type, 2023
Figure 28: Global Peptide API Market Share Analysis, by Product Type, 2034
Figure 29: Global Peptide API Market Volume (Kg) Share Analysis, by Product Type, 2023 and 2034
Figure 30: Global Peptide API Market Share Analysis, by Product Type, 2023
Figure 31: Global Peptide API Market Share Analysis, by Product Type, 2034
Figure 32: Global Peptide API Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 33: Global Peptide API Market Value (US$ Bn), by GLP-1 Receptor Agonist Oral Formulations, 2020-2034
Figure 34: Global Peptide API Market Value Share Analysis, by GLP-1 Receptor Agonist Oral Formulations, 2023 and 2034
Figure 35: Global Peptide API Market Value (US$ Bn), by GLP-1 Receptor Agonist Injectable, 2020-2034
Figure 36: Global Peptide API Market Value Share Analysis, by GLP-1 Receptor Agonist Injectables, 2023 and 2034
Figure 37: Global Peptide API Market Value (US$ Bn), by Insulin Injectables, 2020-2034
Figure 38: Global Peptide API Market Value Share Analysis, by Insulin Injectables, 2023 and 2034
Figure 39: Global Peptide API Market Value (US$ Bn), by Other Peptides, 2020-2034
Figure 40: Global Peptide API Market Value Share Analysis, by Other Peptides, 2023 and 2034
Figure 41: Global Peptide API Market Volume (Kg), by GLP-1 Receptor Agonist Oral Formulations, 2020-2034
Figure 42: Global Peptide API Market Value Share Analysis, by GLP-1 Receptor Agonist Oral Formulations, 2023 and 2034
Figure 43: Global Peptide API Market Volume (Kg), by GLP-1 Receptor Agonist Injectable, 2020-2034
Figure 44: Global Peptide API Market Value Share Analysis, by GLP-1 Receptor Agonist Injectables, 2023 and 2034
Figure 45: Global Peptide API Market Volume (Kg), by Insulin Injectables, 2020-2034
Figure 46: Global Peptide API Market Value Share Analysis, by Insulin Injectables, 2023 and 2034
Figure 47: Global Peptide API Market Volume (Kg), by Other Peptides, 2020-2034
Figure 48: Global Peptide API Market Value Share Analysis, by Other Peptides, 2023 and 2034
Figure 49: Global Peptide API Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Global Peptide API Market Share Analysis, by Route of Administration, 2023
Figure 51: Global Peptide API Market Share Analysis, by Route of Administration, 2034
Figure 52: Global Peptide API Market Volume (Kg) Share Analysis, by Route of Administration, 2023 and 2034
Figure 53: Global Peptide API Market Share Analysis, by Route of Administration, 2023
Figure 54: Global Peptide API Market Share Analysis, by Route of Administration, 2034
Figure 55: Global Peptide API Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 56: Global Peptide API Market Value (US$ Bn), by Oral, 2020-2034
Figure 57: Global Peptide API Market Value Share Analysis, by Oral, 2023 and 2034
Figure 58: Global Peptide API Market Value (US$ Bn), by Parenteral, 2020-2034
Figure 59: Global Peptide API Market Value Share Analysis, by Parenteral, 2023 and 2034
Figure 60: Global Peptide API Market Volume (Kg), by Oral, 2020-2034
Figure 61: Global Peptide API Market Value Share Analysis, by Oral, 2023 and 2034
Figure 62: Global Peptide API Market Volume (Kg), by Parenteral, 2020-2034
Figure 63: Global Peptide API Market Value Share Analysis, by Parenteral, 2023 and 2034
Figure 64: Global Peptide API Market Value (US$ Bn) Share Analysis, by Application, 2023 and 2034
Figure 65: Global Peptide API Market Share Analysis, by Application, 2023
Figure 66: Global Peptide API Market Share Analysis, by Application, 2034
Figure 67: Global Peptide API Market Volume (Kg) Share Analysis, by Application, 2023 and 2034
Figure 68: Global Peptide API Market Share Analysis, by Application, 2023
Figure 69: Global Peptide API Market Share Analysis, by Application, 2034
Figure 70: Global Peptide API Market Attractiveness Analysis, by Application, 2024-2034
Figure 71: Global Peptide API Market Value (US$ Bn), by Type 2 Diabetes Mellitus, 2020-2034
Figure 72: Global Peptide API Market Value Share Analysis, by Type 2 Diabetes Mellitus, 2023 and 2034
Figure 73: Global Peptide API Market Value (US$ Bn), by Type 1 Diabetes, 2020-2034
Figure 74: Global Peptide API Market Value Share Analysis, by Type 1 Diabetes, 2023 and 2034
Figure 75: Global Peptide API Market Value (US$ Bn), by Obesity, 2020-2034
Figure 76: Global Peptide API Market Value Share Analysis, by Obesity, 2023 and 2034
Figure 77: Global Peptide API Market Value (US$ Bn), by Non-alcoholic Fatty Liver Disease, 2020-2034
Figure 78: Global Peptide API Market Value Share Analysis, by Non-alcoholic Fatty Liver Disease, 2023 and 2034
Figure 79: Global Peptide API Market Value (US$ Bn), by Others, 2020-2034
Figure 80: Global Peptide API Market Value Share Analysis, by Others, 2023 and 2034
Figure 81: Global Peptide API Market Volume (Kg), by Type 2 Diabetes Mellitus, 2020-2034
Figure 82: Global Peptide API Market Value Share Analysis, by Type 2 Diabetes Mellitus, 2023 and 2034
Figure 83: Global Peptide API Market Volume (Kg), by Type 1 Diabetes, 2020-2034
Figure 84: Global Peptide API Market Value Share Analysis, by Type 1 Diabetes, 2023 and 2034
Figure 85: Global Peptide API Market Volume (Kg), by Obesity, 2020-2034
Figure 86: Global Peptide API Market Value Share Analysis, by Obesity, 2023 and 2034
Figure 87: Global Peptide API Market Volume (Kg), by Non-alcoholic Fatty Liver Disease, 2020-2034
Figure 88: Global Peptide API Market Value Share Analysis, by Non-alcoholic Fatty Liver Disease, 2023 and 2034
Figure 89: Global Peptide API Market Volume (Kg), by Others, 2020-2034
Figure 90: Global Peptide API Market Value Share Analysis, by Others, 2023 and 2034
Figure 91: Global Peptide API Market Value (US$ Bn) Share Analysis, by Region, 2023 and 2034
Figure 92: Global Peptide API Market Share Analysis, by Region, 2023
Figure 93: Global Peptide API Market Share Analysis, by Region, 2034
Figure 94: Global Peptide API Market Volume (Kg) Share Analysis, by Region, 2023 and 2034
Figure 95: Global Peptide API Market Share Analysis, by Region, 2023
Figure 96: Global Peptide API Market Share Analysis, by Region, 2034
Figure 97: Global Peptide API Market Attractiveness Analysis, by Region, 2023-2034
Figure 98: North America Peptide API Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 99: North America Peptide API Market Value Share Analysis, by Country, 2023 and 2034
Figure 100: North America Peptide API Market Attractiveness Analysis, by Country, 2024-2034
Figure 101: North America Peptide API Market Volume (Kg) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 102: North America Peptide API Market Volume Share Analysis, by Country, 2023 and 2034
Figure 103: North America Peptide API Market Attractiveness Analysis, by Country, 2024-2034
Figure 104: North America Peptide API Market Value (US$ Bn) Share Analysis, by Drug Class, 2023 and 2034
Figure 105: North America Peptide API Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 106: North America Peptide API Market Volume (Kg) Share Analysis, by Drug Class, 2023 and 2034
Figure 107: North America Peptide API Market Attractiveness Analysis, by Drug Class, 2024-2034
Figure 108: North America Peptide API Market Value (US$ Bn) Share Analysis, by Product Type, 2023 and 2034
Figure 109: North America Peptide API Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 110: North America Peptide API Market Volume (Kg) Share Analysis, by Product Type, 2023 and 2034
Figure 111: North America Peptide API Market Attractiveness Analysis, by Product Type, 2024-2034
Figure 112: North America Peptide API Market Value (US$ Bn) Share Analysis, by Route of Administration, 2023 and 2034
Figure 113: North America Peptide API Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 114: North America Peptide API Market Volume (Kg) Share Analysis, by Route of Administration, 2023 and 2034
Figure 115: North America Peptide API Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 116: North America Peptide API Market Value (US$ Bn) Share Analysis, by Application, 2023 and 2034
Figure 117: North America Peptide API Market Attractiveness Analysis, by Application, 2024-2034
Figure 118: North America Peptide API Market Volume (Kg) Share Analysis, by Application, 2023 and 2034
Figure 119: North America Peptide API Market Attractiveness Analysis, by Application, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Peptide API Market
